## **Murat Cokol**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1956891/publications.pdf

Version: 2024-02-01

40 papers

5,151 citations

279798 23 h-index 36 g-index

42 all docs 42 docs citations

42 times ranked

9203 citing authors

#	Article	IF	CITATIONS
1	The Genetic Landscape of a Cell. Science, 2010, 327, 425-431.	12.6	1,937
2	Finding nuclear localization signals. EMBO Reports, 2000, 1, 411-415.	4.5	626
3	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discovery, 2015, 5, 1210-1223.	9.4	575
4	Systematic exploration of synergistic drug pairs. Molecular Systems Biology, 2011, 7, 544.	7.2	284
5	Oxidative Stress Is a Mediator for Increased Lipid Accumulation in a Newly Isolated Dunaliella salina Strain. PLoS ONE, 2014, 9, e91957.	2.5	247
6	Strength of Selection Pressure Is an Important Parameter Contributing to the Complexity of Antibiotic Resistance Evolution. Molecular Biology and Evolution, 2014, 31, 2387-2401.	8.9	222
7	A Protein Domain-Based Interactome Network for C. elegans Early Embryogenesis. Cell, 2008, 134, 534-545.	28.9	196
8	Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discovery Today, 2016, 21, 225-238.	6.4	162
9	Efficient measurement and factorization of high-order drug interactions in <i>Mycobacterium tuberculosis</i> . Science Advances, 2017, 3, e1701881.	10.3	107
10	Chemogenomics and orthologyâ€based design of antibiotic combination therapies. Molecular Systems Biology, 2016, 12, 872.	7.2	96
11	How many scientific papers should be retracted?. EMBO Reports, 2007, 8, 422-423.	4.5	63
12	A Parallel Adder Coordinates Mycobacterial Cell-Cycle Progression and Cell-Size Homeostasis in the Context of Asymmetric Growth and Organization. Current Biology, 2017, 27, 3367-3374.e7.	3.9	62
13	Antibiotic susceptibility signatures identify potential antimicrobial targets in the Acinetobacter baumannii cell envelope. Nature Communications, 2020, 11, 4522.	12.8	62
14	Emergent behavior of growing knowledge about molecular interactions. Nature Biotechnology, 2005, 23, 1243-1247.	17.5	51
15	Prediction of ultra-high-order antibiotic combinations based on pairwise interactions. PLoS Computational Biology, 2019, 15, e1006774.	3 <b>.</b> 2	49
16	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. Journal of Medicinal Chemistry, 2017, 60, 3902-3912.	6.4	45
17	Temporal and intrinsic factors of rifampicin tolerance in mycobacteria. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8302-8307.	7.1	44
18	Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment. PLoS Computational Biology, 2018, 14, e1006677.	3.2	31

#	Article	IF	CITATIONS
19	Target-Independent Prediction of Drug Synergies Using Only Drug Lipophilicity. Journal of Chemical Information and Modeling, 2014, 54, 2286-2293.	5.4	30
20	Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 6843-6855.	2.0	30
21	Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery. Colloids and Surfaces B: Biointerfaces, 2017, 158, 175-181.	5.0	30
22	Large-Scale Identification and Analysis of Suppressive Drug Interactions. Chemistry and Biology, 2014, 21, 541-551.	6.0	27
23	Prediction of synergistic drug combinations. Current Opinion in Systems Biology, 2017, 4, 24-28.	2.6	26
24	Diagonal Method to Measure Synergy Among Any Number of Drugs. Journal of Visualized Experiments, $2018, \dots$	0.3	25
25	Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion. Scientific Reports, 2019, 9, 11876.	3.3	24
26	Modeling the impact of drug interactions on therapeutic selectivity. Nature Communications, 2018, 9, 3452.	12.8	18
27	Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111340.	5.0	18
28	Visualizing evolution and impact of biomedical fields. Journal of Biomedical Informatics, 2008, 41, 1050-1052.	4.3	17
29	Drugs and their Interactions. Current Drug Discovery Technologies, 2013, 10, 106-113.	1.2	14
30	Miniaturized Checkerboard Assays to Measure Antibiotic Interactions. Methods in Molecular Biology, 2019, 1939, 3-9.	0.9	10
31	A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. Scientific Reports, 2021, 11, 11861.	3.3	10
32	Guided screen for synergistic three-drug combinations. PLoS ONE, 2020, 15, e0235929.	2.5	7
33	A drug similarity network for understanding drug mechanism of action. Journal of Bioinformatics and Computational Biology, 2014, 12, 1441007.	0.8	1
34	Characterizing ABC-Transporter Substrate-Likeness Using a Clean-Slate Genetic Background. Frontiers in Pharmacology, 2019, 10, 448.	3.5	1
35	A Novel Composition of Endogenous Metabolic Modulators, AXA4010, Impacts Adhesion, Inflammation and RBC Membrane Deformability in Preclinical Models of Sickle Cell Disease. Blood, 2019, 134, 978-978.	1.4	1
36	Response by Cokol <i>et al</i> . EMBO Reports, 2007, 8, 793-793.	4.5	0

3

#	Article	IF	CITATIONS
37	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		O
38	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		0
39	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		O
40	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		0